Answers are grounded in this paper and cite their sources.
Quality assurance in pharmaceutical manufacturing is conventionally framed as a compliance and product-safety function, yet its influence reaches well beyond conformance to determine whether medicines reach patients consistently and on time. This article advances a conceptual argument that repositions quality assurance as a direct determinant of supply reliability rather than a parallel obligation. Drawing on quality management theory and manufacturing operations research, it traces the mechanisms through which quality assurance systems, including process validation, deviation and change control, supplier qualification, and batch release discipline, govern production continuity, reduce rejected and recalled output, and stabilize the upstream flow of finished product into distribution. The article builds a conceptual model linking quality maturity to downstream availability and ultimately to patient access, and it pinpoints where quality failures convert into supply disruption. By reframing quality assurance as an enabler of reliability and access rather than only a guardian of safety, the article argues for aligning quality and supply objectives in both manufacturing strategy and health-system planning. It offers propositions connecting specific quality practices to availability outcomes and shows how the reconceptualization can inform manufacturer investment decisions and procurement-side supplier evaluation. A research agenda for empirical validation is proposed.
No takes yet. Share an insight, caveat, or question.
Cindy Serwaa Asiedu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: